Immunology

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis

Monday, April 12, 2021 - 7:10am

In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.

Key Points: 
  • In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.
  • The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.\nSIAF, based in Davos, is a world leader within applied allergy and asthma research.
  • Skin barrier assessment shows potential to be clinically useful for early prediction of disease development, improved diagnosis, disease follow-up and therapy evaluation.\nThis study shows that the Nevisense method can directly assess the status of epithelial barrier using electrical impedance spectroscopy (EIS).
  • Furthermore, copy numbers of filaggrin, an essential skin barrier molecule significantly correlated with EIS on non-lesional skin of patients.

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis

Monday, April 12, 2021 - 7:09am

In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.

Key Points: 
  • In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin.
  • The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.\nSIAF, based in Davos, is a world leader within applied allergy and asthma research.
  • Skin barrier assessment shows potential to be clinically useful for early prediction of disease development, improved diagnosis, disease follow-up and therapy evaluation.\nThis study shows that the Nevisense method can directly assess the status of epithelial barrier using electrical impedance spectroscopy (EIS).
  • Furthermore, copy numbers of filaggrin, an essential skin barrier molecule significantly correlated with EIS on non-lesional skin of patients.

Sandia International Launches more Secure, Private Vaccine Pass Technology

Friday, April 16, 2021 - 4:27pm

b'GRAND PRAIRIE, Texas, April 16, 2021 /PRNewswire/ --A first-of-its-kind, secure SMART Health Card solution that stores encrypted vaccination records and identity authenticators is now available from Sandia International, Inc., a secure identification technology provider based in North Texas.

Key Points: 
  • b'GRAND PRAIRIE, Texas, April 16, 2021 /PRNewswire/ --A first-of-its-kind, secure SMART Health Card solution that stores encrypted vaccination records and identity authenticators is now available from Sandia International, Inc., a secure identification technology provider based in North Texas.
  • The card\'s underlying technology is SecuSeal , a proprietary solution that is similar to a QR-code but more intricately encoded, private, tamper-proof, and secure.
  • This new vaccination credential can be accessed and validated digitally, online, and offline.
  • Domestically, even if not required, a vaccine passport could exempt cardholders from strict testing and quarantine requirements.

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

Saturday, April 10, 2021 - 9:13pm

Broad based immune response suggests that GP2 immunotherapy and Herceptin based products may also have the potential to treat other HER2 1-3+ expressing cancers.

Key Points: 
  • Broad based immune response suggests that GP2 immunotherapy and Herceptin based products may also have the potential to treat other HER2 1-3+ expressing cancers.
  • GP2 treated patients, independent of their HER2 status, experienced a potent immune response to GP2, far greater than patients treated with placebo.
  • We believe that monitoring immune response will be an important aspect of the Phase III trial.
  • In the placebo arm, the immune response was not as robust, resulting in 89% disease free survival (11% recurrence rate).

F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster

Saturday, April 10, 2021 - 2:22pm

Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137.

Key Points: 
  • Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137.
  • The early onset of activity and T cell proliferation gives us confidence that FS222 will allow for a wide range of treatment options.
  • Tetravalent binding by FS222 demonstrated optimal activity in multiple preclinical pharmacology studies, outperforming classic heterodimeric bispecific antibodies.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Saturday, April 10, 2021 - 1:30pm

The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.

Key Points: 
  • The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.
  • "We are pleased to announce new in vivo data today that show INTASYL mPH-762 offered strong tumor control in Hepa 1-6 and CT26 models, which are PD-1 responsive and PD-1 refractory models, respectively.
  • "These data further support our excitement around this asset andto bring PH-762 to patients, starting with our first clinical study later this year."
  • Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

Saturday, April 10, 2021 - 1:31pm

The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.

Key Points: 
  • The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.
  • As we are still exploring optimal dosing, these early responses are particularly encouraging, said Joern Aldag, Chief Executive Officer of HOOKIPA.
  • Preliminary data showed a strong antigen-specific T cell response after one dose of HB-201 or HB-202, based on direct Enzyme-Linked ImmunoSpot (ELISpot) T cell analysis.
  • Other preliminary immunogenicity data highlight immune system activation following a single dose of HB-201.

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

Saturday, April 10, 2021 - 1:30pm

Bolt is utilizing its Boltbody platform to create immune-stimulating antibody conjugates (ISACs), such as BDC-1001, that invoke this mechanism and provided complete tumor regression in preclinical tumor models.

Key Points: 
  • Bolt is utilizing its Boltbody platform to create immune-stimulating antibody conjugates (ISACs), such as BDC-1001, that invoke this mechanism and provided complete tumor regression in preclinical tumor models.
  • In murine models we have seen efficacy in a variety of tumors that are immunologically cold and well-established.
  • In a series of preclinical studies with BDC-1001, Bolt demonstrated the mechanism of action for their HER2-targeted ISAC.
  • Bolt expects to provide an update on the trial sometime in the second half of 2021.

MacroGenics Announces Presentations at the 2021 AACR Annual Meeting

Saturday, April 10, 2021 - 1:30pm

ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021.

Key Points: 
  • ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021.
  • This years AACR presentations highlight three antibody-based technologies upon which multiple molecules are being developed at MacroGenics, said Ezio Bonvini, M.D., Senior Vice President and Chief Scientific Officer of MacroGenics.
  • We are presenting pre-clinical data on MGC018, our clinical-stage, investigational antibody-drug conjugate (ADC) targeting B7-H3.
  • Together, these results illustrate the drug development potential of all three technologies MacroGenics is deploying to identify and advance promising anti-cancer drug candidates.

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

Saturday, April 10, 2021 - 1:30pm

The data were presented today in a poster session at the American Association of Cancer Research (AACR) Annual Meeting 2021 (LB118: Mechanisms underlying synergistic activity in MYD88MT DLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrates).

Key Points: 
  • The data were presented today in a poster session at the American Association of Cancer Research (AACR) Annual Meeting 2021 (LB118: Mechanisms underlying synergistic activity in MYD88MT DLBCL of KT-413, a targeted degrader of IRAK4 and IMiD substrates).
  • IRAKIMiDs synergistically target both the MYD88-NFkB and IRF4-Type 1 interferon pathways to enhance and broaden anti-tumor activity in MYD88-mutant DLBCL.
  • KT-413 is being developed initially for the treatment of relapsed/refractory MYD88-mutant DLBCL, with the potential to expand into other MYD88-mutant indications and IL-1R/NFkB-driven malignancies.
  • KT-413 showed superior cell killing compared to the potent IMiD CC-220 or the IRAK4-selective degrader KTX-545 across MYD88-mutant DLBCL cell lines.